604, 2021
Europe approves the first anti PD-1/L1 therapy for patients with MSI-H/dMMR colorectal cancer
On January 26, 2021, the European Medicines Agency approved pembrolizumab [...]
2502, 2021
A breakthrough for the targeted therapy of RET+ tumours with new selective inhibitors
Last year the Food and Drug Administration approved two selective [...]
1612, 2020
Hope of a cure for cholangiocarcinoma coming from FGFR inhibitors
Last April, the Food and Drug Administration granted accelerated approval [...]
2809, 2020
Alpelisib and PIK3CA mutations: a new molecular targeted therapy for breast cancer is approved
On July 27, 2020, the European Medicines Agency authorised marketing [...]
2906, 2020
New European recommendations on DPD testing prior to anticancer therapy with fluoropyrimidines
Last April 30th, the European Medicines Agency (EMA) published recommendations [...]
1604, 2020
A new therapeutic opportunity treatment of NSCLC: the BRAF V600 mutation
FDA and EMA approved and reimbursed dabrafenib + trametinib combination [...]